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Depressive symptoms as a 
side effect of Interferon-α 
therapy induced by induction of 
indoleamine 2,3-dioxygenase 1
Yuki Murakami1,2,*, Takaaki Ishibashi1,*, Eiichi Tomita3, Yukio Imamura1,4, Tomoyuki Tashiro1, 
Kanitta Watcharanurak5, Makiya Nishikawa5, Yuki Takahashi5, Yoshinobu Takakura5, 
Satoko Mitani1,6, Hidetsugu Fujigaki7, Yoshiji Ohta8, Hisako Kubo1, Takayoshi Mamiya9,10, 
Toshitaka Nabeshima10,11,12, Hyoung-Chun Kim13, Yasuko Yamamoto1 & Kuniaki Saito1,8,10
Depression is known to occur frequently in chronic hepatitis C viral (HCV) patients receiving interferon 
(IFN)-α therapy. In this study, we investigated whether indoleamine 2,3-dioxygenase1 (IDO1)-
mediated tryptophan (TRP) metabolism plays a critical role in depression occurring as a side effect of 
IFN-α therapy. Increases in serum kynurenine (KYN) and 3-hydroxykynurenine (3-HK) concentrations 
and in the ratios of KYN/TRP and 3-HK/kynurenic acid (KA) were much larger in depressive HCV patients 
than in non-depressed patients following therapy. Furthermore, transfection of a plasmid continuously 
expressing murine IFN-γ into normal mice significantly increased depression-like behavior. IFN-γ gene 
transfer also resulted in a decrease in serum TRP levels in the mice while KYN and 3-HK levels were 
significantly increased in both serum and frontal cortex. Genetic deletion of IDO1 in mice abrogated 
both the increase in depression-like behavior and the elevation in TRP metabolites’ levels, and the 
turnover of serotonin in the frontal cortex after IFN-γ gene transfer. These results indicate that the KYN 
pathway of IDO1-mediated TRP metabolism plays a critical role in depressive symptoms associated 
with IFN-α therapy.
Hepatitis C viral (HCV) infection affects approximately 170 million people worldwide1. Up to 85% of 
HCV-infected individuals may develop long-term chronic hepatitis C (CHC)2–4. Interferon-α (IFN-α ) is a 
cytokine associated with early viral infection and has both anti-viral and anti-proliferative properties5. The cur-
rent standard of treatment for CHC consists of combination therapy with IFN-α plus ribavirin, which has a broad 
spectrum anti-viral effect. In clinical trials, more than 50% of CHC patients treated with the combination therapy 
achieved a sustained viral response, defined as undetectable HCV in the blood 6 months after the end of the ther-
apy2,6. Despite the potential therapeutic benefits of IFN-α , its administration often causes not only somatic symp-
toms, e.g., anorexia, insomnia, pain, and fever, but also neuropsychiatric symptoms, including depressive states, 
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anhedonia, anxiety, and cognitive impairment7–11. Depression, a serious and frequently occurring side effect of 
IFN-α therapy, is one of the major reasons for cessation of the therapy10,12–15. In order to avoid the discontinuation 
of IFN-α therapy due to its depressive side effects, it is important to identify the contributing factor(s) leading to 
the depressive symptoms.
The metabolism of L-tryptophan (TRP), an essential amino acid, in extrahepatic tissues proceeds through 
the L-kynurenine (KYN) and the serotonin [5-hydroxytryptamine (5-HT)] pathways (see Supplemental Fig. 1S). 
Indoleamine 2,3-dioxygenase1 (IDO1) is the first and rate-limiting enzyme in the KYN pathway and is induced 
by several pro-inflammatory cytokines, including IFNs (IFN-α , β , γ ), tumor necrosis factor (TNF-α ), and inter-
leukin 6 (IL-6) (see Supplemental Fig. 1S)16,17. Recent preclinical studies in mice have demonstrated that either 
pharmacological inhibition of IDO1 enzymatic activity or genetic deletion of IDO1 abrogates acute and chronic 
inflammation-dependent behavioral changes induced by peripheral or central administration of lipopolysaccha-
ride (LPS)18–22. Direct activation of the central cytokine signaling pathway by intracerebroventricular adminis-
tration of TNF-α , LPS, or the human immunodeficiency virus transactivator of transcription in mice develops 
depression-like behavior through the up-regulation of IDO122–25. Additionally, it has been reported that periph-
eral administration of KYN alone can induce depression-like behavior in rats26. KYN in blood is taken up into 
the brain through the blood-brain barrier and is a primary source of several metabolites of the KYN pathway 
in the central nervous system (CNS)27,28. In a clinical study, patients with IFN-α therapy show increases in the 
total Montgomery-Asberg Depression Rating Score (MADRS), an index of depressive symptoms, as well as in 
the KYN/TRP ratio (reflecting IDO1 activity) and the KYN/kynurenic acid (KA) ratio (reflecting the neurotoxic 
challenge)29, although the TRP/competing amino acid (CAA) ratio (reflecting TRP availability to the brain) does 
not significantly change during therapy. These findings suggested that TRP depletion itself may not be required 
for the induction of behavioral changes due to IDO1 activation and that KYN and its neuroactive metabolites are 
more relevant than TRP depletion to cytokine-induced behavioral changes. However, it is still unclear whether 
direct induction of IDO1 and TRP metabolites plays a critical role in depressive symptoms induced by IFN-α 
therapy.
Major depression is accompanied by dysfunction of the serotonergic neuronal system. This includes, for 
example, decreased activity of the central presynaptic 5-HT neurons, which is related to a decreased availabil-
ity of plasma TRP, and changes in postsynaptic receptors30. Further, treatment of rats with IFN-α significantly 
reduces 5-HT in the frontal cortex in a dose-dependent manner31. A clinical study also shows immunotherapy 
with IFN-α significantly increases the severity of depressive symptoms related to the depletion of serum 5-HT 
and induction of the catabolism of TRP to KYN15. These studies suggested that IFN-α -induced changes in the 
serotonergic neuronal function could play a role in the development of IFN-α -induced depressive symptoms. 
However, whether the induction of IDO1 and serotonergic turnover induced by immune activation are directly 
related is still unclear.
In the present study, we examined changes in the serum levels of TRP and its metabolites in patients with 
HCV before and during IFN-α therapy. We also investigated the relationship between changes in serum KYN/
TRP and 3-HK/KA ratios to incidence of depression in patients receiving IFN-α therapy. Mouse IDO1 is induced 
by IFN-γ more markedly than IFN-α 32. Although IFN-α has a weak direct IDO1-stimulating effect, it enhances 
IDO1 activity indirectly by stimulating IFN-γ production33,34. Therefore, we investigated whether IDO1 activity 
induced by IFN-γ gene transfer impaired behavior in mice. Metabolic abnormalities of the KYN pathway have 
been detected in the frontal cortex in a murine model of major depression35. Thus, we also measured the con-
centration of TRP metabolites in the serum and frontal cortex of normal mice after IFN-γ gene transfer. Finally, 
we examined the effect of IDO1 gene-deficiency on depression-like behavior, the levels of TRP metabolites, and 
changes of 5-HT turnover in the frontal cortex after IFN-γ gene transfer.
Results
Clinical characteristics of HCV patients undergoing IFN-α therapy. The characteristics of HCV 
patients who received IFN-α therapy are shown in Table 1. Among 49 HCV patients, 32 were male and 17 female. 
No significant differences were found between depression-negative (− ) and depression-positive (+ ) HCV 
patients in their age, the ratio of gender, HCV genotype, or aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) levels (Table 1).
Depression (− ) Depression (+)
All subjects 30 (Male: 20; Female: 10) 19 (Male: 12; Female: 7)
Age 54.33 ± 2.06 54.0 ± 2.29
HCV genotype 1b 24 (80%) 15 (78.9%)
HCV genotype 2a 4 (13.3%) 3 (15.8%)
HCV genotype 2b 2 (6.7%) 1 (5.3%)
AST 59.43 ± 5.09 57.47 ± 6.45
ALT 82.68 ± 11.36 69.56 ± 8.65
Table 1.  Clinical characteristics of HCV patients undergoing IFN-α therapy. “Depression (− )”: HCV 
patients without depression, “Depression (+ )”: HCV patients with depression following IFN-α therapy. HCV; 
hepatitis C virus, AST; aspartate aminotransferase, ALT; alanine aminotransferase.
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Changes in the levels of serum TRP and its metabolites in HCV patients receiving IFN-α therapy. 
Figure 1a shows serum TRP, KYN, KA, and 3-HK concentrations in HCV patients before the onset of IFN-α 
therapy and at 2 and 4 weeks after the onset of therapy. In depression (+ ) patients, compared to values before 
the onset of therapy, serum TRP concentration tended to decrease while serum KYN concentration increased 
significantly at 2 weeks. Serum 3-HK concentration increased significantly at both 2 and 4 weeks after the onset 
of therapy. There was a no significant change in serum KA level, but it tended to decrease at either time point. In 
depression (− ) patients, serum KYN and 3-HK concentrations increased at 2 and 4 weeks compared to values 
before the onset of therapy, but not significant. Further, serum TRP and KA concentrations tended to decrease, 
but not significant. During IFN-α therapy, the increased levels of serum KYN and 3-HK tended to be higher in 
depression (+ ) patients than in depression (− ) patients and there were significant increases of 3-HK level in 
depression (+ ) patients than in depression (− ) patients at 2 weeks after the onset of therapy (Fig. 1 and Table 2). 
Figure 1. Changes in the levels of serum TRP and its metabolites in HCV patients undergoing IFN-α 
therapy. (a) The Y axis shows TRP, KYN, KA, and 3-HK concentrations in HCV patients at 2 and 4 weeks after 
the onset of therapy, expressed as a percentage of the concentration before IFN-α therapy. (b) Serum KYN/TRP 
and 3-HK/KA ratios in HCV patients are shown as a percentage of values before IFN-α therapy. Rectangles 
indicate non-depressive HCV patients [Depression (− )]; circles indicate HCV patients with depressive 
symptoms [Depression (+ )]. Each data point represents the mean ± SEM of values obtained from n = 30 
depression (− ) patients and n = 19 depression (+ ) patients. *p < 0.05, ***p < 0.001 versus before the onset of 
IFN-α therapy, #p < 0.05, ##p < 0.01 versus depression (− ) patients. Detailed statistical analyses are in Tables 2 
and 3.
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No changes in serum anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-HAA) levels were detected at 2 and 
4 weeks during IFN-α therapy in both depression (+ ) and depression (− ) patients (Table 2).
To determine the relationships between the changes in serum levels of TRP and its metabolites and the devel-
opment of depression in HCV patients undergoing IFN-α therapy, serum KYN/TRP (reflecting IDO1 activity) 
and 3-HK/KA (reflecting neurotoxic indices) were examined. We investigated these ratios before the onset of the 
therapy and at 2 and 4 weeks after the onset of therapy. In depression (− ) patients, serum KYN/TRP and 3-HK/
KA ratios increased at 2 and 4 weeks after the onset of therapy, and the increased levels of these ratios were similar 
at both time points (Fig. 1b and Table 2b). In depression (+ ) patients, serum KYN/TRP ratio increased signifi-
cantly at 4 weeks after the onset of therapy while the serum 3-HK/KA ratio increased significantly at both 2 and 
4 weeks after the onset of therapy. Moreover, the increased levels of KYN/TRP and 3-HK/KA ratios tended to 
be higher in depression (+ ) patients than in depression (− ) patients and there were significant increases of both 
ratios in depression (+ ) patients than in depression (− ) patients at 4 weeks after the onset of therapy (Fig. 1b and 
Table 3).
Abnormal behavior in a forced swimming test after IFN-γ gene transfer in mice. In order to 
clarify whether the induction of IDO1 by IFN-γ affects behavior, three tests, open-field test (OFT), the Y-maze 
test, and forced swimming test (FST), were conducted in mice. Mice were transfected with either a pCpG-Muγ 
plasmid that continuously expressed IFN-γ [IFN-γ transfected (+ ) mice] or a control plasmid (pCpG-mcs) that 
did not contain the IFN-γ gene [IFN-γ transfected (− ) mice]. In the OFT, no significant differences in locomotion 
or the number of rearing were detected between IFN-γ transfected (+ ) and (− ) mice (Fig. 2a). Similarly, in the 
Y-maze test, no significant differences in the number of arm entries and alternation behavior were found between 
the two groups of mice (Fig. 2b). However, in the FST, immobility time was significantly longer in IFN-γ trans-
fected (+ ) mice (Fig. 2c, Student’s t test, t(34) = 2.286, p = 0.0286).
% of value before IFN-α therapy
t df p valueDepression (− ) Depression (+)
2 w after onset of therapy
 TRP 95.4 ± 2.93 100.5 ± 3.98 0.965 40 0.340
 KYN 108.6 ± 4.77 118.1 ± 4.24* 1.200 39 0.237
 3-HK 117.0 ± 7.13 152.6 ± 10.4***, ## 2.886 38 0.006
 KA 97.4 ± 5.51 95.9 ± 7.13 0.136 38 0.892
 AA 119.9 ± 7.42 115.5 ± 7.11 0.381 41 0.706
 3-HAA 102.9 ± 6.53 121.8 ± 12.6 1.452 37 0.155
4 w after onset of therapy
 TRP 92.0 ± 2.55 93.3 ± 6.49 0.213 39 0.833
 KYN 104.8 ± 4.38 114.4 ± 6.38 1.204 39 0.236
 3-HK 123.0 ± 9.01 155.0 ± 11.5*** 2.005 36 0.053
 KA 91.9 ± 5.12 88.8 ± 6.98 0.341 40 0.735
 AA 107.5 ± 5.32 103.6 ± 11.3 0.361 40 0.720
 3-HAA 101.9 ± 6.52 104.5 ± 14.8 0.182 36 0.857
Table 2.  Changes in the levels of serum TRP and its metabolites in HCV patients undergoing IFN-α 
therapy. Percent value of serum TRP, KYN, 3-HK, KA, AA, and 3-HAA concentrations in HCV patients 
at 2 and 4 weeks after onset of therapy, compared with the concentration (100%) before IFN-α therapy. In 
the clinical samples, some metabolites were difficult to separate clearly by HPLC. Therefore, the degree of 
freedom (df) values differ by the measured molecules. “Depression (− )”: the HCV patients without depression, 
“Depression (+ )”: the HCV patients with depression. *p < 0.05, ***p < 0.001 versus before the therapy, ##p < 0.01 
versus Depression (− ).
% of value before IFN-α therapy
t df p valueDepression (− ) Depression (+)
2 w after onset of therapy
 KYN/TRP 115.6 ± 4.55 114.1 ± 5.95 0.198 42 0.844
 3-HK/KA 129.1 ± 9.52 144.0 ± 9.06* 1.036 39 0.308
4 w after onset of therapy
 KYN/TRP 115.7 ± 5.69 138.3 ± 8.84*,# 2.094 35 0.044
 3-HK/KA 129.6 ± 8.67 171.1 ± 18.6***,# 2.325 35 0.026
Table 3.  Changes in serum KYN/TRP and 3-HK/KA ratios in HCV patients undergoing IFN-α therapy. 
Serum KYN/TRP, reflecting IDO1 activity, and 3-HK/KA, reflecting neurotoxic indices, both ratios in HCV 
patients were shown as % of value compared with the value (100%) before IFN-α therapy, at 2 and 4 weeks after 
onset of therapy. *p < 0.05, ***p < 0.001 versus before the therapy, #p < 0.05 versus Depression (− ).
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Changes in the levels of TRP and its metabolites in the serum and frontal cortex of mice after 
IFN-γ gene transfer. Mice were euthanized immediately following behavioral testing for the determination 
of the levels of TRP, KYN, KA, 3-HK, 3-HAA, and AA in the serum and the frontal cortex. Serum TRP concen-
tration was significantly lower in IFN-γ transfected (+ ) mice compared to IFN-γ transfected (− ) mice. In con-
trast, KYN and 3-HK serum levels were significantly higher in the IFN-γ transfected (+ ) mice. However, there 
were no significant differences in KA, 3-HAA, and AA serum concentrations between the two groups (Fig. 3a). 
In the frontal cortex, IFN-γ transfected (+ ) mice had significantly higher KYN and 3-HK levels than the IFN-γ 
transfected (− ) mice. There were no significant differences in TRP, KA, 3-HAA, and AA levels between the two 
groups, although the TRP and KA levels in the frontal cortex tended to be lower in the IFN-γ transfected (+ ) 
mice (Fig. 3b).
Effects of IDO1 gene-deficiency on depressive behavior, changes in TRP metabolism, serotonin 
levels and serotonin turnover in the mouse frontal cortex after IFN-γ-gene transfer. We eval-
uated the role of IDO1 in the development of depressive-like behavior after IFN-γ gene transfer using IDO1 
gene knockout (K.O.) mice. Mice were subjected to a forced swimming test as described above. The increase of 
time spent in an immobile posture in the IFN-γ transfected (+ )/wild type mice was significantly improved in 
IDO1 K.O. mice (Fig. 4a, two-way ANOVA, FIDO1 KO (1, 33) = 10.84, p = 0.0024; FIFN-γ (1, 33) = 0.16, p = 0.6962, 
FIDO1 KO x IFN-γ (1, 33) = 7.88, p = 0.0083).
In wild type mice, IFN-γ gene transfer significantly increased the concentrations of KYN and 3-HK in 
the frontal cortex by a factor of 4.7- and 2.5-fold, respectively, but had no significant effect on TRP and KA 
(Fig. 4b). In contrast, IDO1 K.O. mice reversed these changes in IFN-γ gene transfer mice (Fig. 4b). After IFN-γ 
gene transfer, KYN and 3-HK levels in the frontal cortex were significantly lower in IDO1 K.O. mice than in 
wild type mice (for KYN, two-way ANOVA, FIDO1 KO (1, 36) = 57.67, p < 0.0001; FIFN-γ (1, 36) = 28.70, p < 0.0001, 
FIDO1 KO x IFN-γ (1, 36) = 27.20, p < 0.0001; for 3-HK, two-way ANOVA, FIDO1 KO (1, 14) = 44.52, p < 0.0001; 
FIFN-γ (1, 14) = 31.15, p < 0.0001, FIDO1 KO x IFN-γ (1, 14) = 21.66, p = 0.0004), but there were no significant differences 
in TRP and KA levels between the two groups (for TRP, two-way ANOVA, FIDO1 KO (1, 23) = 1.86, p = 0.1855; 
FIFN-γ (1, 23) = 1.51, p = 0.2314, F IDO1 KO x IFN-γ (1, 23) = 0.65, p = 0.4291; for KA, two-way ANOVA, FIDO1 KO (1, 19) = 0.72, 
p = 0.4052; FIFN-γ (1, 19) = 0.06, p = 0.812, FIDO1 KO x IFN-γ (1, 19) = 0.22, p = 0.6432).
To study the neurochemical basis of depression-like behavior in wild type mice after IFN-γ gene transfer, the 
amounts of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the frontal cortex of wild type and 
IDO1 K.O. mice were compared (Fig. 4c). Compared to IFN-γ transfected (− )/wild type mice, the level of 5-HT 
was slightly decreased and the level of 5-HIAA was increased in the frontal cortex of IFN-γ transfected (+ )/ 
wild type mice. Therefore, the 5-HIAA/5-HT ratio increased, reflecting the turnover of 5-HT in IFN-γ trans-
fected (+ )/wild type mice (Fig. 4c). In the frontal cortex of IFN-γ transfected (− )/IDO1 K.O. mice, 5-HT and 
Figure 2. Abnormal behavior in a forced swimming test after IFN-γ gene transfer in mice. The open bar 
shows control plasmid (empty pCpG-mcs vector)-injected mice [IFN-γ transfected (− ) mice]; closed bar shows 
mice received the pCpG-Muγ plasmid, which continuously expresses murine IFN-γ [IFN-γ -transfected (+ ) 
mice]. (a) Locomotor activity and rearing of IFN-γ -transfected (+ ) and (− ) mice in a novel environment in an 
open field test. (b) Short-term memory in a Y-maze test for the two groups of mice. Alternation behavior and 
total arm entries were measured in an 8 min session. (c) Immobility of IFN-γ -transfected (+ ) and (− ) mice in a 
forced swimming test. Each column represents the mean ± SEM (n = 9–16). * p < 0.05 versus IFN-γ -transfected 
(− ) mice.
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5-HIAA levels were slightly higher compared to IFN-γ transfected (− )/wild type mice with no significant change 
in 5-HIAA/5-HT ratio. After IFN-γ gene transfer, 5-HT levels in the frontal cortex of IFN-γ transfected (+ ) 
/IDO1 K.O. mice were significant higher, although there was a slight decrease in 5-HIAA content compared 
with that of IFN-γ transfected (+ )/wild type mice (Fig. 4c, for 5-HT, two-way ANOVA, FIDO1 KO (1, 49) = 8.73, 
p = 0.0048; FIFN-γ (1,49) = 0.00, p = 0.9643, FIDO1 KO x IFN-γ (1, 49) = 1.39, p = 0.2448; for 5-HIAA, two-way ANOVA, 
FIDO1 KO (1, 50) = 0.17, p = 0.6852; FIFN-γ (1,50) = 1.05, p = 0.3098, FIDO1 KO x IFN-γ (1, 50) = 4.57, p = 0.0374). 5-HT turno-
ver (i.e., the 5-HIAA/5-HT ratio) was significantly lower in the frontal cortex of IFN-γ transfected (+ )/IDO1 K.O. 
mice compared to that of IFN-γ transfected (+ )/wild type mice (Fig. 4c, two-way ANOVA, FIDO1 KO (1, 49) = 8.71, 
p = 0.0048, FIFN-γ (1,49) = 0.08, p = 0.7749, FIDO1 KO x IFN-γ (1, 49) = 6.94, p = 0.0112).
Discussion
Previous studies suggested that IDO1-mediated TRP metabolism may be implicated in the development 
of depression, a side effect of IFN-α therapy in HCV patients. To further clarify the relationship between the 
IDO1-induced KYN pathway and the development of depressive symptoms during IFN-α therapy, we measured 
TRP metabolites of the KYN pathway in the serum of HCV patients undergoing IFN-α therapy. We found that 
HCV patients showed decreased TRP and increased KYN concentrations without any changes in KA, AA, and 
3-HAA concentrations during IFN-α therapy (Fig. 1a and Table 2). Further, depression (+ ) patients showed a 
larger increase in 3-HK concentration compared to depression (− ) patients during therapy (Table 2). Ogawa et al. 
recently showed that mean plasma TRP was significantly decreased in major depressive disorder (MDD) patients 
versus healthy controls36. Teraishi et al. also demonstrated increased TRP metabolism along the KYN–NAD path-
way, but not the KYN–KA pathway, in patients with MDD37. Our results are consistent with these findings. We 
also compared the ratios of KYN/TRP (reflecting IDO1 activity) and 3-HK/KA (reflecting neurotoxic indices)38,39 
between depression (+ ) and depression (− ) patients during IFN-α therapy (Fig. 1b and Table 3). In both groups, 
the ratios of KYN/TRP and 3-HK/KA increased during therapy. However, in depression (+ ) patients, the ratios 
of KYN/TRP and 3-HK/KA increased by a much greater degree than in depression (− ) patients during therapy 
(Table 3). In these patients, the serum KYN/TRP and 3-HK/KA ratios tended to further increase at the diagno-
sis of depression, but at 70.3 ± 9.1 days after the end of therapy, they returned to the same levels as before the 
onset of the therapy. The severity of depressive symptoms was not assessed during therapy, e.g., using neither the 
Hamilton Depressing Rating Scale nor MADRS, therefore, we could not clearly show the relationship between 
the exacerbation of depression and changes of TRP metabolites. However, our results suggest that HCV patients 
who have a high sensitivity for IDO1 induction by IFNs are more susceptible to the depression-related side effects 
of IFN-α therapy.
We also examined behavioral changes and TRP metabolites in IFN-γ -transfected (+ ) mice, which showed 
high induction of IDO1 in the brain. Previous studies have shown that all three IFNs (IFN-α , -β and -γ ) induced 
strong IDO1 activity in human peripheral blood mononuclear cells40,41. In contrast, mouse IDO1 is induced more 
Figure 3. Changes in the levels of TRP and its metabolites in the serum and frontal cortex of mice after 
IFN-γ gene transfer. TRP-KYN metabolite concentrations were determined in the serum (a) and the frontal 
cortex (b) of mice at 28 days after IFN-γ -gene transfer. The open bar shows IFN-γ -transfected (− ) mice, and the 
closed bar shows IFN-γ -transfected (+ ) mice. Each column represents the mean ± SEM (n = 15–20).  
* * p < 0.01, * * * p < 0.001 versus IFN-γ -transfected (− ) mice.
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markedly by IFN-γ than IFN-α , which has only a weak direct IDO1-stimulating effect32. To confirm this, we 
administered a single i.p. injection of either mouse recombinant (mr) IFN-α or mrIFN-γ to mice to compare the 
induction of IDO1 activity (see Supplemental Fig. 3S). We found that mrIFN-γ significantly increased the activity 
of IDO1, whereas mrIFN-α showed a very weak IDO1 induction in mice, consistent with former research (see 
Supplemental Figs 3S and 4S)32. Additionally, our previous studies also demonstrated that the response of IDO1 
activity to systemic and/or CNS immune activation and inflammation depends on species and cell types17. These 
results suggest that human cells, more so than mice cells, are highly responsive to IDO1 induction by IFN-α . We 
hypothesized that the high induction of IDO1 and the imbalance of TRP metabolites induced by IFNs in humans 
may be related to psychiatric side effects such as depression. Therefore, we selected IFN-γ gene transfer to induce 
a high IDO1 activity and cause the imbalance of TRP-KYN pathway rather than IFN-α in our animal model. 
However, species difference for the response of IDO1 induction might be one of the limitations in this study.
The current results indicate that IDO1 induction by IFN-γ is a critical factor in depressive-like behaviors but 
not in short-term memory or locomotor activity in mice. The induction of IDO1 by IFN-γ gene transfer signifi-
cantly changed the levels of TRP and its metabolites in the serum and frontal cortex of mice (Fig. 3). These results 
suggest that an alternative interpretation for the involvement of IDO1 in IFN-γ -induced depressive-like behavior 
is the generation of neuroactive TRP metabolites. Although we cannot exclude the possibility that genetic dele-
tion of IDO1 and the resulting alterations in TRP metabolites affect other behavioral tests, our results show mice 
deficient in IDO1 do not develop depressive-like behavior and do not increase TRP metabolites after IFN-γ gene 
transfer (Fig. 4). This interpretation is consistent with our clinical data and previous studies by O’Connor et al. 
and Wichers et al.18,29.
An alternative interpretation for the involvement of IDO1 in cytokine-induced depression is the generation 
of neuroactive TRP metabolites. While KYN itself is not neuroactive, it readily crosses the blood brain barrier 
Figure 4. Effects of IDO1 gene-deficiency on depressive behavior, changes in TRP metabolism, serotonin 
levels and serotonin turnover in the mouse frontal cortex after IFN-γ-gene transfer. (a) A forced swim test 
was performed 28 days after IFN-γ -gene transfer in wild type mice and IDO1 K.O. mice. The Y axis shows % 
value of immobility time in IFN-γ -transfected (+ ) mice, compared with the time (100%) in IFN-γ -transfected 
(− ) mice. Actual immobility times in IFN-γ -transfected (− ) and (+ )/wild type mice were 118.9 ± 162.1 and 
160.9 ± 137.0 sec, respectively. While, actual immobility times in IFN-γ -transfected (− ) and (+ )/IDO1 K.O. 
mice were 188.1 ± 78.0 and 146.5 ± 171.0 sec, respectively (n = 8–15). The level of TRP metabolites (b) and 
the amount of 5-HT, 5-HIAA, and 5-HIAA/5-HT ratio as an index of serotonin turnover (c) in the frontal 
cortex of mice at 28 days after IFN-γ -gene transfer (n = 6–15). The open bar shows wild type; the closed bar, 
IDO1 K.O. mice. IFN-γ -transfected (− ) mice were injected with the control plasmid (pCpG-mcs), and IFN-γ 
-transfected (+ ) mice were injected with the IFN-γ -expressing pCpG-Muγ plasmid. Each column represents 
the mean ± SEM. * p < 0.05, * * * p < 0.001 versus IFN-γ -transfected (− ) wild type mice, #p < 0.05, ##p < 0.01, 
###p < 0.001 versus IFN-γ -transfected (+ ) wild type mice.
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via the large neutral amino acid transporters27. In the brain, KYN is taken up by glia cells, where it is further 
metabolized into neuroactive compounds such as 3-HK, KA, which are direct metabolites of KYN, and quin-
olinic acids (QUIN). When IDO1 is upregulated, KYN metabolism shifts from the predominant production of 
KA toward the generation of increased amounts of 3-HK and QUIN. 3-HK and QUIN generate free radicals, 
and QUIN also acts as an N-methyl-D-aspartate (NMDA) receptor agonist. Both metabolites are considered 
excitotoxic compounds in the brain. Preclinical, in vitro, and post-mortem data demonstrate that the elevated 
concentrations of these neurotoxic KYN metabolites are associated with neuronal damage and/or suppression of 
neurogenesis. KA is a glutamate receptor antagonist, which is also reported to inhibit the alpha 7 nicotinic ace-
tylcholine receptors. Earlier studies of KA demonstrated that it can be neuroprotective against neuronal damage 
caused by neurotoxic QUIN, an effect that is most likely mediated through inhibitory activity at NMDA recep-
tors42. More recent studies have demonstrated decreases in plasma KA and the KA/QUIN ratio in patients with 
depression39,43 while increased KA levels have been reported in the cerebrospinal fluid and postmortem brain of 
schizophrenia patients. Sustaining physiological levels of KA are likely important in maintaining a basal neuro-
protective environment within the brain, but pathophysiologically elevated levels of KA could contribute to cog-
nitive deficits and a reduction of dopaminergic and glutamatergic neurotransmission44. Conceivably, the relative 
effects of 3-HK and QUIN versus KA are dependent on the type of disorder (e.g., MDD versus schizophrenia). 
Therefore, IFN-α treatment may directly and/or indirectly stimulate IDO1 induction and thereby promote the 
KYN pathway, which results in increased levels of neuroactive compounds and an imbalance of TRP metabolites 
in the brain. Neuroactive TRP metabolites such as 3-HK, QUIN, and KA may promote oxidative stress, cell death, 
and excessive glutamate release that can cause neuronal damage and behavioral changes45,46. More experiments 
blocking KYN metabolizing enzymes, e.g., kynurenine-3-monooxygenase (KMO) or kynurenine aminotrans-
ferase II (KAT II), will clarify whether KYN induces depressive-like behavior by itself or after further generation 
of its downstream neuroactive metabolites.
Other studies have emphasized that the serotonin (5-HT) pathway is also relevant to depression. Dysfunction 
of the 5-HT pathway contributes to the development of depressive symptoms, but many antidepressants affecting 
5-HT reuptake attenuates the symptoms. Moreover, selective serotonin reuptake inhibitors (SSRIs) have been 
shown to improve depressive symptoms during IFN-α therapy47. As the level of 5-HT in peripheral blood may 
not reflect the actual level of 5-HT in the brain, we did not measure 5-HT level in the serum of HCV patients. 
However, TRP and 5-hydroxytryptophan, a precursor of 5-HT, were significantly decreased from baseline in the 
serum of HCV patients during IFN-α therapy48. Barton et al. demonstrated that brain 5-HT turnover was ele-
vated in non-medicated patients with MDD and was influenced by the serotonin transporter (5-HTT) genotype49. 
Thus, we speculate that biological mechanisms underlying the IFN-α treatment induced-depressive symptoms 
are linked not only to the activated IDO1 and KYN pathway but also to a dysfunction of the 5-HT system.
IFN-γ -induced depressive-like behavior appears to be dependent on IFN-γ -induced changes in the KYN 
pathway via IDO1 induction and also on increased 5-HT turnover, a parameter of serotonergic neuronal activity 
(Fig. 4c). Increases in IDO1 activity have the potential to inhibit serotoninergic neurotransmission by decreasing 
the bioavailability of TRP. Although a significant decrease in peripheral levels of TRP was observed after IFN-γ 
gene transfer, brain TRP and 5-HT levels were not significantly affected. IFN-α and –γ are known to increase 
5-HT reuptake and the transcription rate of 5-HTT mRNA50. The increase in 5-HT reuptake would be expected 
to decrease synaptic 5-HT. 5-HIAA is produced by intraneuronal deamination (via monoamine oxidase A) of 
5-HT after either leakage of the neurotransmitter into the axoplasm from storage vesicles or reuptake of the neu-
rotransmitter after exocytotic release. The contribution of the latter process is reflected by the decrease in 5-HIAA 
production after neuronal uptake blockade. We found that IFN-γ gene transfer caused a non-significant trend 
towards increased 5-HIAA levels in wild type mice but not in IDO1 K.O. mice, indicative of a potential increase 
in IDO1-induced 5-HT turnover following IFN-γ gene transfer. An elevated 5-HT turnover suggests a process 
by which the availability of 5-HT to be released by neurons is lowered to compensate for neuronal dysfunction 
related to depressive-like behavior induced by IFN-γ gene transfer. Previous studies also have shown that brain 
5-HT turnover is substantially elevated in non-medicated MDD patients and reduced following SSRI therapy49,51. 
Taken together, an alternative interpretation for the involvement of IDO1 in IFN-γ -induced depressive-like 
behavior may be that depression is related to not only the generation of neuroactive TRP metabolites but also the 
alteration of serotoninergic neurotransmission.
In conclusion, the present study indicates that IDO1 is a critical molecular regulator of IFNs-induced depres-
sive symptoms. Moreover, the depressive symptoms are induced via increases in the degradation of TRP along the 
KYN pathway and changes in 5-HT turnover. Our findings suggest that inflammatory pathways that lead to the 
activation of IDO1 may be novel therapeutic targets in patients suffering from inflammation-associated depres-
sion, e.g., as is the case during HCV or cancer therapy. However, further insight into the role of each downstream 
KYN pathway metabolite in the pathological process is still needed to clarify the relationship of this pathway to 
various other neurotransmitters.
Materials and Methods
Samples. HCV Patients undergoing IFN-α therapy. Forty nine patients (32 males and 17 females; mean age 
54.0 ± 2.3 years) suffering from chronic hepatitis C were recruited from Gifu Municipal Hospital, Gifu, Japan. 
Table 1 shows the clinical characteristics of patients with HCV. All patients received IFN-α therapy. In this study, 
21 (42.9%) patients received recombinant (r) IFN-α 2b, and 21 (42.9%) patients were treated with pegylated 
(PEG)-IFN-α 2b. Five patients (10.2%) received natural (n) IFN-α , and others were treated with rIFN-α 2a 
(2.0%) and PEG-IFN-α 2a (2.0%), respectively. All interferons have nearly the same efficacy and bring about the 
same activation of the KYN pathway52. The regular duration of treatment was 48 weeks for PEG-IFN-α 2a and 
2b at a dose of 180 μ g (1.5 μ g/kg)/week, and ribavirin at a dose of 600 mg/day (body weight ≤ 60 kg), or 800 mg/
day (body weight 61–80 kg), or 1000 mg/day (body weight > 80 kg). The duration of other IFN-α treatments, 
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including rIFN-α 2a, 2b, and nIFN-α , was normally 24 weeks at a dose of 300–900 MIU/day, with or without 
ribavirin (800 mg/day). No patient had a past history of psychiatric treatment, and all were free from depression 
before IFN-α therapy. No patients received antidepressant medication during the study period. At an average of 
104.2 ± 15.8 days after the onset of IFN-α therapy, some patients presented with depressed mood, apathy, mel-
ancholy, social isolation tendencies, and an intention to stop taking IFN. The patients who felt depressed mood 
were referred for psychiatric evaluation and diagnosed with MDD by a psychiatrist. Nineteen of the HCV patients 
were diagnosed with depressive symptoms [depression (+ )] while 30 of them exhibited no depressive symptoms 
[depression (− )]. Based on clinical interviews, diagnosis to verify the incidence of depressive symptoms for MDD 
was made according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders fourth edition) and 
ICD-10 (International Statistical Classification of Disease and Related Health problems-10). Informed consent 
was obtained from each patient. The study protocol conformed to the ethical guidelines of the 1975 Declaration 
of Helsinki as reflected in a priori approval by the medical research ethics committee of Kyoto University and Gifu 
Municipal Hospital, and all experiments were performed in accordance with approved guidelines and regulations.
Preparation of serum samples from HCV patients. For all HCV patients, blood was collected before the onset of 
IFN-α therapy and 2 and 4 weeks after the onset of the therapy, and there was a no significant time difference for 
sampling blood between depression (− ) and (+ ) patients (see Supplemental Table 1S and Fig. 2S). Serum was 
separated from the blood by low-speed centrifugation (800 × g, 15 min) at 4 °C and stored at − 80 °C until analy-
sis. The frozen serum was thawed at room temperature and then mixed with one volume of 10% (v/v) perchloric 
acid for deproteinization. After incubation for 10 min on ice, the mixture was centrifuged at 14,000 × g for 10 min 
at 4 °C, and the resultant supernatant was used for the measurement of TRP and its metabolites KYN, KA, AA, 
3-HK, and 3-HAA.
Experimental animals. All mice were 8-week-old males. IDO1 K.O. mice, of a C57BL/6J background were 
obtained from Jackson Laboratory (Bar Harbor, ME). Wild -type C57BL/6J mice were obtained from SHIMIZU 
Laboratory Supplies Co., Ltd. (Kyoto, Japan). Animals were housed in the Kyoto University School of Medicine 
animal facilities under specific pathogen-free conditions and were maintained on a 12-hour light/dark cycle 
(lights on at 8:00 a.m.) at 25 °C. Mice had free access to food and water. The protocols for animal experiments 
were approved by the Animal Experimentation Committee of the Graduate School of Medicine, Kyoto University, 
and all experiments were performed in accordance with approved guidelines and regulations.
In vivo IFN-γ gene transfer. Plasmid pCpG-Muγ was constructed by inserting a BglII/NheI murine IFN-γ 
cDNA fragment into the BglII/NheI site of the pCpG-mcs vector (InvivoGen, San Diego, CA) as described pre-
viously53,54. The prepared plasmid pCpG-Muγ was dissolved in normal saline and injected into the tail veins of 
the mice over 5 sec on day 055,56. The injection volume was approximately 9% (v/w) of body weight. The doses 
of pCpG-Muγ used were 0.01, 0.05, and 0.1 pmol/mouse. To eliminate the possibility of tissue damage and/or 
inflammation by the hydrodynamic injection, a control plasmid, which was the empty vector without the IFN-γ 
gene (pCpG-mcs), was injected (0.05 pmol/mouse) [IFN-γ transfected (− ) mice]. We confirmed that the injected 
plasmid pCpG-Muγ [IFN-γ transfected (+ ) mice] significantly increased IDO1 activity in the lung and frontal 
cortex at 0.05 or 0.1 pmol/mouse (see Supplemental Fig. 5S) compared to IFN-γ transfected (− ) mice. Therefore, 
the plasmid dose was fixed at 0.05 pmol/mouse throughout all experiments, which corresponded to 0.10–0.12 μ 
g of DNA/mouse.
Behavioral tests. All behavioral tests were performed between 9:00 a.m. and 6:00 p.m. 4 weeks after IFN-γ 
gene transfer. The behavioral tests were conducted in the following order: the Y-maze test, OFT, and then FST.
Spontaneous alternation behavior of mice in a Y-maze, an index of short-term memory, was performed 
according to the method outlined in previous reports57,58. The Y-maze apparatus consisted of black-painted ply-
wood, with each arm measuring 40 × 10 × 12 cm (L × W × H), tapering to 3-cm wide at the bottom. The arms 
converged to a triangular center, 4 cm per side. Each mouse was placed at the end of an arm and allowed to move 
freely throughout the maze during an 8-min session. The series of arm entries was recorded visually. Spontaneous 
alternation behavior was defined as the entry into all three arms (i.e., arm A, arm B, and arm C) on consecutive 
choices in triplet sets (i.e., ABC, ACB, BAC, BCA, CAB and CBC). Alternation behavior was calculated as the 
ratio of actual alternations to possible alternations (defined as the total number of arm entries-2) × 100, and listed 
as a percentage, as described previously57,58.
The OFT using a Letica model LE 8811 (Bioseb, France) was performed according to the method described 
previously59. To measure locomotor activity in a novel environment, a mouse was placed in a transparent acrylic 
cage with a black frosted Plexiglas floor (45 × 45 × 30 cm), and locomotion behaviors and rearing were measured 
every 1 min for 10 min using digital counters with infrared sensors (SCANET MV-40 OF; MELQUEST Co., Ltd., 
Toyama, Japan).
The FST is a standardized test of depressive-like behavior for which depression is inferred from increased 
durations of immobility. This test was conducted as described previously60, with slight modifications. Each mouse 
was placed in a transparent glass cylinder (20 cm high, 8 cm in diameter) that contained water at 22 ± 1 °C to a 
depth of 13.5 cm and was forced to swim for 300 sec. The duration of swimming was measured using a SCANET 
MV-40 AQ apparatus (MELQUEST Co., Ltd., Toyama, Japan). The duration of immobility was recorded during 
the last 5 min of the 6-minute test. The mice were subjected to 15 min training under similar conditions, 24 h 
before the test.
Preparation of serum and tissue samples from experimental animals. Immediately after the end of 
all behavioral tests, mice were sacrificed under sodium pentobarbital (50 mg/kg of body weight, i.p.) anesthesia, 
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and blood was collected from the abdominal vena cava. Serum was separated from the blood by low-speed cen-
trifugation (1,000 × g, 10 min). Serum samples for the measurements of TRP and its metabolites were prepared 
in the same way as for HCV patients.
Immediately after sacrifice, the whole brain was isolated from each mouse, and the frontal cortex was dissected 
from the brain. Each frontal cortex was placed in a polypropylene tube and immediately frozen by immersion in 
liquid nitrogen and kept at − 80 °C until analysis. Tissue samples for measurements of TRP and its metabolites 
were prepared by homogenizing the frontal cortex in 1.5 volumes of 3% perchloric acid. Each homogenized 
sample was maintained at 4 °C overnight and then centrifuged at 12,000 × g for 20 min at 4 °C. The resultant 
supernatant was loaded onto an Ultrafree-MC Centrifugal Filter Unit with a Microporous Membrane (0.45 μ m 
Cat UFC30HV00, Millipore) and centrifuged at 12,000 × g for 4 min at 4 °C.
Laboratory assessments. All biological samples were analyzed by research staff blinded to the clinical and 
experimental status of study participants.
Measurements of TRP and its metabolites. TRP, KYN, KA, AA, 3-HK, and 3-HAA in the serum of 
HCV patients and the serum and frontal cortex of mice were measured by high-performance liquid chromatogra-
phy (HPLC) using a spectrophotometric (UV detector, SPD-20A, Shimadzu Co., Kyoto, Japan) or a fluorescence 
spectrometric detector (RF-10AXL, Shimadzu Co., Kyoto, Japan). TRP, KYN, AA, and KA were separated on a 
reverse phase chromatography column (TSK-GEL ODS-100 V 3 μ m, 150 mm × 4.6 mm, i.d. 3 μ m particle size, 
TOSOH Co., Tokyo, Japan) with a mobile phase of 100 mM zinc acetate, 10 mM sodium acetate (pH6.2), and 2% 
(v/v) acetonitrile at a flow rate of 1.0 ml/min. UV signals initially were monitored at 365 nm to detect KYN. After 
18 min, UV was measured at 230 nm to detect TRP. The fluorescence excitation and emission wavelengths were 
set at 320 and 420 nm for 3-HAA and AA, respectively. After 15 min, excitation and extension wavelengths were 
changed to 344 and 404 nm, respectively, for KA. 3-HK was measured by HPLC with an electrochemical detector, 
Eicom ECD-300 (+ 550 mV) and a chromatographic column (EICOMPAK SC-50DS, 150 mm × 3.0 mm, i.d. 3 μ m 
particle size, Eicom Co., Kyoto, Japan) with a mobile phase of 0.59% (v/v) phosphoric acid, 0.34 mM EDTA, 
14 mM heptanesulfonic acid, 0.9% (v/v) triethtlamine and 1% (v/v) acetonitrile at a flow rate of 0.5 ml/min. In the 
clinical samples, some metabolites were difficult to separate clearly by HPLC, and we excluded the data which did 
not show the single peak.
Measurements of 5-HT and 5-HIAA. 5-HT and 5-HIAA were measured in the frontal cortex of mice 
by the method described previously61. Briefly, 5-HT and 5-HIAA were determined using HPLC with an elec-
trochemical detector, Eicom ECD-300 (+ 750 mV), and a chromatographic column (EICOMPAK SC-50DS, 
150 mm × 3.0 mm, i.d. 3 μ m particle size, Eicom Co., Kyoto, Japan) with a mobile phase of 83% (v/v) 0.1 M acetic 
acid-citric acid buffer (pH3.5) containing 0.88 mM sodium 1-octanesulfonate, 0.015 mM EDTA, and 17% (v/v) 
methanol at a flow rate of 0.5 ml/min. Each frozen brain sample was weighed and homogenized with an ultra-
sonic processor in 0.2 M perchloric acid containing isoproterenol as an internal standard. The homogenates were 
placed on ice for 30 min and centrifuged at 20,000 × g for 15 min. The resultant supernatants were mixed with 1 M 
sodium acetate to adjust the pH to 3.0 and injected into an HPLC system. The serotonin turnover was estimated 
by the ratio of 5-HIAA/5-HT.
Statistical analysis. The data (mean ± SEM) from patients were analyzed by group, controlling for age 
and gender. The comparison of the mean values of the parameters, which showed normal distributions between 
depression (+ ) and depression (− ) patients, was performed using Student’s t-test, the Mann-Whitney test, and a 
one-way analysis of variance (ANOVA) with the Bonferroni post hoc test. A two-tailed p value of less than 0.05 
was considered statistically significant. Results from animal experiments were also expressed as mean ± SEM. 
Intergroup comparisons were made using one-way or two-way ANOVAs, followed by the Bonferroni’s/Dunn’s 
multiple range test. Statistical analyses and graphing were performed using GraphPad Prism version 5.0 
(GraphPad Software, San Diego, USA). A p value of less than 0.05 was considered statistically significant.
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